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This Research Topic was conceived to provide a venue for investigators to document their critical
contributions to our understanding of the cellular and molecular mechanisms that provide our
remarkable immune system the capacity to protect us from environmental insults while simulta-
neously remaining unreactive to our internal molecular milieu. Although the scientific literature
gives one a history of what happened, when it happened, and who were responsible, it fails to
capture precisely how things came together, and why some investigators were successful, while
others working contemporaneously failed. Thus, seminal contributors were asked to recount the
various aspects of their experiments and people who were instrumental in making the progress that
moved our understanding forward.
Looking back over the brief history of immunology, a discipline that arose after the pioneering
approaches of Edward Jenner introduced the smallpox vaccine in 1798 (1) and Louis Pasteur
catapulted immunology into universal awareness 100 years later (2–4), the science has only become
mature within the past 50 years. For almost 100 years after Pasteur, experimentalists focused on
observations of the reactions of whole experimental animals or humans to the administration of
putative antigenic substances. For the first time, around 1960, it was appreciated that lymphocytes
are the cells that mediate the immune reaction (5–7), and experimentation moved for the first time
from in vivo to in vitro, which allowed one to manipulate and investigate an immune reaction of
cell populations “outside of the black box.” During the 1960s, various techniques were improved so
that it was possible to discern that several different types of cells cooperated to ultimately generate
a measurable immune response, usually monitored by the appearance of antibody-forming cells
(AFCs) (8, 9).
As detailed in this Research Topic, by the 1970s, experiments culminated in the demonstration
that two distinct types of lymphocytes existed, termed thymic-derived cells (T cells) and bone
marrow-derived cells (B cells), which generate AFCs. Furthermore, a third type of cell derived
from myeloid cells, termed an antigen-presenting cell (APC), also played a role. Evidence was also
presented that there are at least two distinct subsets of T cells. Moreover, investigators detected
activities in culture supernatants of activated lymphocyte populations that seemed to enhance or
suppress the generation of AFCs as well as the proliferation of various lymphocytes. However, the
molecular basis of these activities remained enigmatic and essentially unapproachable, given the
experimental biochemical methods then available.
Four new and novel experimental methods were introduced in the 1970s that revolutionized
all of biological sciences, which enabled a further reduction from cells to molecules, and led to
the discipline that now can be recognized as molecular immunology. In 1972, the flow cytometer
introduced a new method to identify and isolate individual cells present in cell populations (10).
Also, genetic engineering approaches enabled investigators to identify and isolate complimentary
DNA molecules encoding gene products, which then allowed the ready determination of their
primary structures, and provided a means to generate essentially unlimited quantities of critical
proteins (11). Third, the advent in 1975 of the capacity to isolate and clone individual AFCs, which
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could produce unlimited quantities of monoclonal antibody
molecules (12), could then be used to identify and isolate both
individual cells using the flow cytometer, but also new reagents
that could be used to isolate and purify individual protein
molecules from complex mixtures.
The fourth critical technical advance, which like mono-
clonal antibodies was also special to immunology, was the cre-
ation in 1979 of the methods to select, clone, and grow the
functional progeny of individual T cells (13). This advance,
for the first time, allowed one to circumvent the tremen-
dous heterogeneity of individual cells within T cell popula-
tions so that the molecules responsible for antigen recognition,
histocompatibility restriction, and the molecular mechanisms
underlying T cell function, including T cell help of anti-
body production and T cell mediated cytolysis, could be
uncovered.
The contributions comprising this compilation of the sto-
ries about how the transition from experiments on whole living
organisms to cell populations to individual cells and finally to
homogeneous molecules represent a unique aspect of scientific
communication, in that they tell the behind the scenes dramas
that are usually left out of the scientific literature. This Research
Topic tells how science gets done, andwhat the people are like who
actually do it. I hope that you enjoy the stories.
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